《多发性骨髓瘤相关静脉血栓栓塞症防治中国专家共识(2022年版)》解读

Interpretation of expert consensus on the prevention and treatment of multiple myeloma related venous thromboembolism in China(2022)

多发性骨髓瘤(MM)是一种浆细胞克隆性增殖的恶性疾病。静脉血栓栓塞症(VTE)是MM常见的并发症之一,关键在于预防、早期诊断和治疗,但我国一直以来缺乏更进一步规范MM相关VTE防治的共识。结合国内外研究和指南,中华医学会血液学分会浆细胞疾病学组和血栓与止血学组共同制定了《多发性骨髓瘤相关静脉血栓栓塞症防治中国专家共识(2022年版)》。为更好地指导临床实践,文章拟对该共识的诊断部分、风险评估部分、分层预防部分(包括肾功能不全和血小板减少患者)和治疗部分进行解读。

Multiple myeloma(MM)is a malignant disease characterized by the clonal proliferation of plasma cells.Venous thromboembolism(VTE)is one of the common complications of MM,and the key is prevention,early diagnosis,and early treatment.However,there has been a lack of relevant consensus on further standardizing the prevention and treatment of MM-related VTE in China.Combined with domestic and foreign research and guidelines,the Plasma Cell Disease Group and the Thrombosis and Hemostasis Group of the Hematology Branch of the Chinese Medical Association jointly formulated the"Expert Consensus on the Prevention and Treatment of Multiple Myeloma-related Venous Thromboembolism in China(2022 edition)".To better guide clinical practice,this paper intends to interpret the diagnostic part,the risk assessment part,the stratified prevention part(including patients with renal insufficiency and thrombocytopenia),and the treatment part of this consensus.